Lucid Diagnostics

Canaccord Genuity Acted as the Sole Bookrunner to Lucid Diagnostics Inc. on its $17.3 Million Public Offering

Canaccord Genuity is pleased to announce that on April 11, 2025, it completed a public offering of common stock for Lucid Diagnostics Inc. (NASDAQ: LUCD) (the “Company”). The offering comprised of 14,375,000 shares of common stock, including the exercise in full of the underwriter’s option to purchase additional shares, at a public offering price of $1.20 per share, resulting in gross proceeds of $17.3 million. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

Canaccord Genuity acted as the sole bookrunner for the offering.

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM). The Company is focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. The Company’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.